Alvogen Claims Lead On Lenalidomide In Europe

 
• By Dave Wallace

Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.

RacingCar
Alvogen Says It Is In Pole Position For European Lenalidomide • Source: Shutterstock

More from Generics

More from Products